Clinical and prognostic features of patients with detailed RAS/BRAF-mutant colorectal cancer in Japan

BMC Cancer

Hironaga Satake¹  Nobuhiro Shibata¹  Shogen Boku¹  Mototsugu Shimokawa²  Masahito Kotaka³  Hisateru Yasui⁴  Toshihiko Matsumoto⁴  Hiroki Nagai⁴  Tatsuki Ikoma⁴ 

[1] Cancer Treatment Center, Kansai Medical University Hospital, 2-3-1, Shinmachi, 573-1191, Hirakata, Osaka, Japan;Department of Biostatistics, Yamaguchi University Graduate School of Medicine, 755-0046, Ube, Japan;Department of Gastrointestinal Cancer Center, Sano Hospital, 655-0031, Kobe, Japan;Department of Medical Oncology, Kobe City Medical Center General Hospital, 650-0047, Kobe, Japan;

关键词: Colorectal cancer;    KRAS;    KRAS;    NRAS;   

DOI  :  10.1186/s12885-021-08271-z

来源: Springer

【 摘 要 】

BackgroundRAS/BRAFV600E mutations are the most remarkable oncogenic driver mutations in colorectal cancer (CRC) and play an important role in treatment selection. No data are available regarding the clinical and prognostic features of patients with detailed RAS/BRAFV600E-mutant metastatic CRC (mCRC) in Japan.MethodsA total of 152 chemotherapy-naïve patients with mCRC were included in this study between August 2018 and July 2019. Tumor samples were collected, and RAS/BRAFV600E status was investigated. RAS/BRAFV600E status was examined using a MEBGEN RASKET-B kit and polymerase chain reaction reverse sequence-specific oligonucleotide method.ResultsRAS/BRAFV600E mutations were detected in 54% of cases (KRAS codon 12, 26%; KRAS codon 13, 17%; KRAS non-Exon2, 5%; NRAS, 5%; and BRAFV600E, 7%). BRAFV600E-mutant CRC mainly existed in the right colon, whereas KRAS non-Exon2 and NRAS-mutant CRC was predominantly present in the left colon. KRAS non-Exon2 and NRAS-mutant CRC were associated with shorter survival time than RAS wild-type CRC (hazard ratio [HR], 2.26; 95% confidence interval [CI], 0.64–8.03; p = 0.19; HR, 2.42; 95% CI, 0.68–8.61; p = 0.16) and significantly shorter overall survival than KRAS Exon2-mutant CRC (HR, 3.88; 95% CI, 0.92–16.3; p = 0.04; HR, 4.80; 95% CI, 1.14–20.2; p = 0.02).ConclusionsIn our multicenter study, the findings elucidated the clinical and prognostic features of patients with detailed RAS/BRAFV600E-mutant mCRC in Japan.

【 授权许可】

CC BY